Bevacizumab + Paclitaxel + Capecitabine in Triple Negative Metastatic Breast Cancer

Phase 2TerminatedNCT01069796

ARCAGY/ GINECO GROUP64 enrolled

Overview

Patients with triple negative metastatic breast cancer (HER2-, PR-, ER-) will receive bevacizumab, paclitaxel and capecitabine as a first line of treatment (possibility to have received adjuvant chemotherapy).

Study Type

INTERVENTIONAL

Allocation

Purpose

TREATMENT

Masking

NONE

Enrollment

Conditions

Triple Negative Metastatic Breast Cancer

Interventions

PaclitaxelDRUG

80 mg/m² weekly

BevacizumabDRUG

10 mg/kg d1 d15

CapecitabineDRUG

800 mg/m² p.o. twice a day, D1 to D5 week 1, 2 \& 3

Eligibility

Sex: FEMALEMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Female histologically confirmed adenocarcinoma of the breast ER-, PR-, HER2- disease * Measurable disease * Patients may received prior radiotherapy as adjuvant treatment or/and metastatic disease provided that they have progressive disease at study entry Exclusion Criteria: * Prior chemotherapy for metastatic disease * HER2 positive and/or hormonal receptor positive

Locations (17)

Centre Paul Papin

Angers, France

Clinique Tivoli

Bordeaux, France

Centre Hospitalier William Morey

Chalon-sur-Saône, France

Outcomes

Primary Outcomes

objective response rate

Time frame: 36 months for recrutment and 30 months for follow up

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.